Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples